Dexcom Continuous Glucose Monitoring (CGM) Systems

Dexcom, Inc. is a pioneering American medical device company that revolutionized diabetes management through its continuous glucose monitoring (CGM) systems. Founded on May 1, 1999, in San Diego, California, by Dr. John Burd and a team of experts, the company was born from a mission to replace intermittent fingerstick blood sugar tests with real-time, actionable data.

Manufacturing for Dexcom is a global operation. Historically centered in San Diego and Mesa, Arizona, the company has expanded its production footprint to include a major facility in Batu Kawan, Malaysia, and a state-of-the-art European site in Athenry, County Galway, Ireland. This diversification ensures a stable global supply chain for its flagship products, such as the Dexcom G6, G7, and the more recently introduced Stelo biosensor.

As of 2026, Dexcom remains a publicly traded independent company (NASDAQ: DXCM). Its ownership is predominantly held by large institutional investors such as The Vanguard Group and BlackRock, which reflect its status as a major player in the S&P 500 and Nasdaq-100 indices. The brand is globally recognized for its technological leadership and its role in the evolution of wearable healthcare.